Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise notably Monday, on the happy news that an analyst has initiated coverage with an unambiguous buy recommendation.

With that at its back, the commercial-stage biotech's share price zoomed more than 5% higher, comparing most favorably to the bellwether S&P 500's (SNPINDEX: ^GSPC) 0.3% decrease.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

A clear buy, says analyst

The initiating party was JMP Securities' Reni Benjamin, who that morning launched his Summit coverage with an outperform (i.e., buy) rating and a $32-per-share price target. That level is a muscular 60% above the stock's most recent closing price, indicating Benjamin's very bullish take on the company.

According to reports, the pundit's optimistic take is based on what he considers Summit's successful pivot to oncology drugs (it initially focused on infectious diseases). He pointed specifically to encouraging phase 3 trial results for ivonescimab, the cancer treatment it licensed in 2023, in the treatment of lung cancer in a study conducted in China.

Although some are skeptical of the accuracy of clinical data coming from that country, Benjamin believes that market has reached sufficient maturity for such results to be accepted by the healthcare community and investors.

Onward with ivonescimab

While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a winning strategy. Lung cancer continues to be a health scourge in many parts of the world, and if the biotech is successful with its current development ambitions with ivonescimab, it can do quite well.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $22,292!*

• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,169!*

• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $407,758!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.